Dr. Soh I Peng, Thomas

Medical Oncology (Cancer)

Credentials MBBS (Singapore), MRCP (United Kingdom)
Language English, Mandarin, Malay, Hokkien

Dr Thomas Soh is a Consultant Medical Oncologist at OncoCare Cancer Centre.  He is also an accredited medical practitioner by the Office of the Public Guardian, to assist patients with making a Lasting Power of Attorney (LPA).

He was previously Consultant at the Department of Haematology Oncology at National University Hospital(NUH) and Visiting Consultant at Ng Teng Fong General Hospital. He graduated from National University of Singapore in 2003 and received his Membership of the Royal College of Physician (United Kingdom) in 2007. He later completed his advance specialist training in Medical Oncology in 2012.

He was heavily involved in both undergraduate and postgraduate education, and was core faculty for the both the Internal Medicine Residency program and the Oncology Senior Residency program in the National University Hospital from 2012 to 2016.  He was recognised for his mentorship and a good teacher to junior doctors and medical students, with the Teaching Excellence Award in 2014, from National University Cancer Institute (NCIS), as well as the Best Tutor Award in 2015 for undergraduate teaching by the University Medical Cluster, NUH.

Dr Soh believes in the delivery of quality healthcare, and was the lead and co-lead in several healthcare improvement projects. He had received multiple awards for his involvement in the Clinical Practice Improvement Programmes that he had implemented in NUH. From 2013-2015, he contributed a leading role being the Honorary Secretary of the Executive Committee, Singapore Society of Oncology.

Dr Soh is actively involved in both research and education in cancer medicine. He had received funding for his work from the National Medical Research Council, Singapore, being awarded the Clinical Investigator Salary Support Program (CISSP) award 3 times. He had researched on drug response and toxicity in treating cancer, understanding how chemotherapy and targeted medications is absorbed and cleared in the body in relation to the pharmacokinetics and pharmacodynamics. He had published on genetic variants affecting chemotherapy in Asian breast cancer patients. His research publication in colorectal cancer involves working with cell free DNA,  chemotherapy drugs Regorafenib, FOLFIRI regimen (irinotecan, 5-fluorouracil and folinic acid).

Dr Soh’s subspecialty interest is in Gastrointestinal (oesophageal, gastric, colon and rectal cancer) and Hepatobiliary Cancer (liver, pancreas, bile duct and gallbladder cancers). He is also a cancer specialist who looks after patients with neuroendocrine cancers. He speaks fluent English, Mandarin, Malay, Bahasa as well as Hokkien and has looked after many Indonesian and Malay patients. He has looked after many international patients, including Vietnamese, Myanmar, Banglahdeshi  and Cambodian patients as well, with the help of interpreters.


​He was the principal investigator in several multi-centre gastrointestinal cancer clinical trials and his research work has lead to more than 10 publications in high impact medical and oncology journals. He was the Principal Investigator for studies of circulating tumour cells, and was also doing trials in hepatocellular cancer (hepatoma) with drugs such as Sorafenib, Lenvatinib, Carbozantinib. The colorectal cancer trials involved drugs such as Cetuximab (Erbitux) with FOLFOX (Oxaliplatin, 5-fluorouracil and folinic acid), FOLFIRI regimens, Aflibercept and Y90 (Therasphere). In advanced pancreatic cancer, he was principal investigator for studies using Gemcitabine, Masitinib, and Abraxane. These experiences stand him in good stead to care for cancer patients and he is recognised for his dedication and expertise in these areas.

  • Awarded Teaching Excellence Award in 2014, NCIS

  • Awarded NUH UMC Undergraduate Teaching Best Tutor Award in 2015

  • Research funding from the National Medical Research Council (NMRC), Singapore, being awarded the Clinical Investigator Salary Support Program (CISSP) award 3 times

  • Research work was published in more than 10 publications relating to hepatocellular carcinoma, colorectal cancer, pancreatic cancer and other gastrointestinal cancers.

  • Subspecialty oncology interest in gastrointestinal (oesophageal, stomach, colon and rectal cancers) and hepatobiliary cancers (liver, pancreas, bile duct and gallbladder cancers)